Abstract 569P
Background
Artificial intelligence (AI) algorithms have been developed to distinguish MMR-D from MMR-P (proficient) tumors, yet they lack biological interpretability. To address this shortcoming, we used validated AI algorithms to detect and quantify well described morphological features in colon cancers from whole slide images.
Methods
Digital images of stage III colon carcinomas from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147; Alliance) were utilized. Available MMR-D (n=191) and randomly selected MMR-P (n=188) cancers were analyzed. QuantCRC quantifies the amount of stroma and stromal subtypes (immature, mature, inflammatory) and tumor/stroma ratio in addition to grade, mucin, signet ring cells, budding/poorly differentiated clusters (TB/PDC) and tumor-infiltrating lymphocytes (TILs). We also distinguished TILs in epithelium vs stromal using another AI algorithm (Lunit SCOPE IO). Area under the curve (AUC), i.e., discrimination threshold, was measured for each feature to predict MMR status.
Results
Among AI-derived morphological features, significant differences were found by MMR status whereby dMMR cancers had lower immature stroma but higher inflammatory stroma, higher tumor grade, and increased mucin, signet ring cells, tumor size, TB/PDCs, and TILs (all Kruskal-Wallis p<0.05). Univariately, AUC (95% CI) values for prediction of MMR status above 0.6 were as follows: TILs 0.72 (0.67-0.77), immature stroma 0.67 (0.62-0.73); inflammatory stroma 0.67 (0.62-0.73); tumor grade 0.65 (0.60-0.71); signet ring cells 0.65 (0.60-0.71); mucin 0.64 (0.59-0.70). Given that TILs in the overall tumor was most discriminant, we then utilized a TIL-specific AI algorithm measuring TILs in epithelium and stroma and found that epithelial TILs had a significantly higher AUC [ 0.79 (0.74-0.84) compared to stromal TILs 0.58 (0.52-0.63) p<0.0001].
Conclusions
Among morphological tumor features quantified by AI, tumor immature desmoplastic stroma and TILs, particularly epithelial TIL densities, were best able to distinguish MMR-D from MMR-P tumors. These findings have implications for prognosis and subtype-based interventions and can guide spatial molecular interrogation.
Clinical trial identification
NCT00079274.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Supported by Institutional grant support. NIH U10CA180821, U10CA180882, U24CA196171, R01 CA210509 (to FAS). Study NCCTG N0147 received funds from Sanofi.
Disclosure
G. Park, Y. Lim: Financial Interests, Institutional, Member: Lunit. D. Yan, K. Shanmugam: Financial Interests, Institutional, Full or part-time Employment: Roche. C-Y. Ock: Financial Interests, Institutional, Member: Lunit. All other authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10